CO2022006718A2 - Compuestos bicíclicos y métodos para su uso en el tratamiento del síndrome de pitt hopkins - Google Patents

Compuestos bicíclicos y métodos para su uso en el tratamiento del síndrome de pitt hopkins

Info

Publication number
CO2022006718A2
CO2022006718A2 CONC2022/0006718A CO2022006718A CO2022006718A2 CO 2022006718 A2 CO2022006718 A2 CO 2022006718A2 CO 2022006718 A CO2022006718 A CO 2022006718A CO 2022006718 A2 CO2022006718 A2 CO 2022006718A2
Authority
CO
Colombia
Prior art keywords
treatment
methods
hopkins syndrome
bicyclic compounds
pitt hopkins
Prior art date
Application number
CONC2022/0006718A
Other languages
English (en)
Inventor
Patricia Cogram
Jonathan Pilcher
Lawrence Irwin Glass
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of CO2022006718A2 publication Critical patent/CO2022006718A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las modalidades de esta invención proporcionan compuestos, composiciones, métodos y usos para dicetopiperazinas terapéuticas, que incluyen G-2-alil prolina cíclica y otros compuestos de Prolina-Glicina cíclica para tratar el síndrome de Pitt Hopkins y sus síntomas, así como la fabricación de composiciones, medicamentos que incluyen tabletas, cápsulas, formulaciones líquidas, geles, soluciones inyectables y otras formulaciones que son útiles para el tratamiento de dichas condiciones.
CONC2022/0006718A 2019-10-22 2022-05-20 Compuestos bicíclicos y métodos para su uso en el tratamiento del síndrome de pitt hopkins CO2022006718A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924452P 2019-10-22 2019-10-22
PCT/US2020/029739 WO2021080646A1 (en) 2019-10-22 2020-04-24 Bicyclic compounds and methods for their use in treating pitt hopkins syndrome

Publications (1)

Publication Number Publication Date
CO2022006718A2 true CO2022006718A2 (es) 2022-08-09

Family

ID=75620281

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0006718A CO2022006718A2 (es) 2019-10-22 2022-05-20 Compuestos bicíclicos y métodos para su uso en el tratamiento del síndrome de pitt hopkins

Country Status (12)

Country Link
US (1) US20230301994A9 (es)
EP (1) EP4048264A4 (es)
JP (1) JP2022553060A (es)
KR (1) KR20220106123A (es)
CN (1) CN115243688A (es)
AU (1) AU2020369431A1 (es)
BR (1) BR112022007636A2 (es)
CA (1) CA3158406A1 (es)
CL (1) CL2022001023A1 (es)
CO (1) CO2022006718A2 (es)
IL (1) IL292408A (es)
WO (1) WO2021080646A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023009482A (es) * 2021-02-12 2023-10-23 Neuren Pharmaceuticals Ltd Tratamientos del sindrome de prader-willi.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519127B2 (en) * 2003-09-03 2013-08-27 Mike John Bickerdike Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
JP6574769B2 (ja) * 2013-07-25 2019-09-11 ニューレン ファーマシューティカルズ リミテッド 二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法

Also Published As

Publication number Publication date
US20220387426A1 (en) 2022-12-08
CL2022001023A1 (es) 2023-03-10
EP4048264A1 (en) 2022-08-31
KR20220106123A (ko) 2022-07-28
AU2020369431A1 (en) 2022-06-09
IL292408A (en) 2022-06-01
WO2021080646A1 (en) 2021-04-29
CN115243688A (zh) 2022-10-25
BR112022007636A2 (pt) 2022-07-12
EP4048264A4 (en) 2023-11-29
US20230301994A9 (en) 2023-09-28
JP2022553060A (ja) 2022-12-21
CA3158406A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CY1123058T1 (el) Νευροπροστατευτικες δικυκλικες ενωσεις και μεθοδοι για τη χρηση τους στη θεραπεια διαταραχων του φασματος του αυτισμου και νευροαναπτυξιακων διαταραχων
CO2019004945A2 (es) Inhibidores de la magl
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2020013550A2 (es) Inhibidores de magl
DOP2012000246A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CR20130580A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CL2019003398A1 (es) Inhibidores pirazólicos de magl.
BR112019004691A2 (pt) inibidores bicíclicos em espiro da interação menina-mll
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
UY37971A (es) Derivados de indol macrocíclicos sustituidos
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CL2019003397A1 (es) Inhibidores pirazólicos de magl.
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
BR112016027435A2 (pt) formulação inovadora de meloxicam
CL2015001187A1 (es) Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades.
CL2019002583A1 (es) Inhibidores duales de magl y faah.
BR112017010602A2 (pt) análogos de ureia ligados em ponte substituídos como moduladores de sirtuína
BR112023018237A2 (pt) Fenalquilaminas e métodos para fabricação e uso das mesmas